The quarterly report due at the end of July will be interesting in terms of their cash receipts and cash burn levels.
Ultimately we’d like to see an increase in revenue from FebriDx and a reduction in cash burn. If both of those can be achieved in the current quarter then I would expect a re-rate.
Cash burn levels will be a significant pointer to whether a further CR would be required.
